In addition to these multifaceted roles during early infection, pDCs have also drawn interest due to their ability to reactivate virus from latently-infected cells, having been associated with decreases in CD4+ T cell proviral load in suppressed patients upon combined latency-reversal agent and TLR agonist treatment (251–255). This evidence concerns the gene CD4 and infection.